Abound™治疗转移性结肠癌中抗表皮生长因子受体（EGFR）抗体相关皮肤疾病疗效的病例报告

A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer.

作者信息

Matsuhashi Nobuhisa, Takahashi Takao, Nonaka Kenichi, Ichikawa Kengo, Yawata Kazunori, Tanahashi Toshiyuki, Imai Hisashi, Sasaki Yoshiyuki, Tanaka Yoshihiro, Okumura Naoki, Yamaguchi Kazuya, Osada Shinji, Yoshida Kazuhiro

机构信息

Surgical Oncology, Gifu University School of Medicine, 1-1 Yanagido, Gifu City 501-1194, Japan.

出版信息

World J Surg Oncol. 2014 Feb 11;12:35. doi: 10.1186/1477-7819-12-35.

DOI:10.1186/1477-7819-12-35

PMID:24517087

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3922949/

Abstract

BACKGROUND

Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments.

CASE PRESENTATION

A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued.

CONCLUSION

We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy.

摘要

背景

帕尼单抗是一种全人源表皮生长因子受体（EGFR）单克隆抗体，是一种用于转移性结直肠癌治疗的药物。抗EGFR单克隆抗体治疗最常见的不良事件之一是皮肤疾病。目前，尽管预防皮肤疾病对于癌症治疗的持续进行很重要，但尚无有效的预防性治疗方法。

病例报告

一名73岁男性，患有乙状结肠癌并伴有同步肺转移，接受帕尼单抗治疗，这是一种单独使用的抗EGFR单克隆抗体，作为三线治疗。在九个疗程的治疗中，疗效为疾病稳定（SD），但皮肤疾病逐渐明显出现（CTCAE第4.0版：2级）。在使用Abound™ 1个月后，皮肤疾病症状改善（CTCAE第4.0版：1级），因此可以继续进行抗体治疗。